UroGen Pharma Ltd (NAS:URGN)
$ 13.05 -0.76 (-5.5%) Market Cap: 549.59 Mil Enterprise Value: 437.91 Mil PE Ratio: 0 PB Ratio: 18.74 GF Score: 72/100

Urogen Pharma Ltd at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2021 / 09:30PM GMT
Release Date Price: $20.29 (-3.59%)
Eric William Joseph
JPMorgan Chase & Co, Research Division - VP & Senior Analyst

Thanks for tuning into the JPMorgan Healthcare Conference. I'm Eric Joseph, senior biotech analyst. Our next presenting company is UroGen Pharma and it's my pleasure at welcome CEO, Liz Barrett, to tell us a little bit about the company.

There is a Q&A after the presentation. Simply click the ask-a-question icon to submit it, and I'll ask on your behalf. With that, Liz, thanks again for sharing some of your time with us.

Elizabeth A. Barrett
UroGen Pharma Ltd. - President, CEO & Director

Yes. Thanks, Eric. Really appreciate you having me.

Hello, everyone. It's so nice to be here. I have to say JPMorgan always holds a special place for me because 2 years ago, when I started in this position, my second day on the job, I was actually at JPMorgan, and I think my fifth day on the job, I was actually presenting the company to JPMorgan attendees. And I have to say I'm a little bit more comfortable today than I was then, part of it that I'm sitting in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot